Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

被引:288
作者
Holst, Frederik
Stahl, Phillip R.
Ruiz, Christian
Hellwinkel, Olaf
Jehan, Zeenath
Wendland, Marc
Lebeau, Annette
Terracciano, Luigi
Al-Kuraya, Khawla
Jaenicke, Fritz
Sauter, Guido
Simon, Ronald [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, D-20246 Hamburg, Germany
[2] Univ Basel Hosp, Dept Pathol, CH-4031 Basel, Switzerland
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, D-20246 Hamburg, Germany
[5] King Faisal Specialist Hosp & Res Ctr, Riyadh 21211, Saudi Arabia
关键词
D O I
10.1038/ng2006
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Using an Affymetrix 10K SNP array to screen for gene copy number changes in breast cancer, we detected a single-gene amplification of the ESR1 gene, which encodes estrogen receptor alpha, at 6q25. A subsequent tissue microarray analysis of more than 2,000 clinical breast cancer samples showed ESR1 amplification in 20.6% of breast cancers. Ninety-nine percent of tumors with ESR1 amplification showed estrogen receptor protein overexpression, compared with 66.6% cancers without ESR1 amplification ( P < 0.0001). In 175 women who had received adjuvant tamoxifen monotherapy, survival was significantly longer for women with cancer with ESR1 amplification than for women with estrogen receptor - expressing cancers without ESR1 amplification ( P = 0.023). Notably, we also found ESR1 amplification in benign and precancerous breast diseases, suggesting that ESR1 amplification may be a common mechanism in proliferative breast disease and a very early genetic alteration in a large subset of breast cancers.
引用
收藏
页码:655 / 660
页数:6
相关论文
共 26 条
[1]   Prognostic relevance of gene amplifications and coamplifications in breast cancer [J].
Al-Kuraya, K ;
Schraml, P ;
Torhorst, J ;
Tapia, C ;
Zaharieva, B ;
Novotny, H ;
Spichtin, H ;
Maurer, R ;
Mirlacher, M ;
Köchli, O ;
Zuber, M ;
Dieterich, H ;
Mross, F ;
Wilber, K ;
Simon, R ;
Sauter, G .
CANCER RESEARCH, 2004, 64 (23) :8534-8540
[2]  
ANDERSEN J, 1989, CANCER, V64, P1901, DOI 10.1002/1097-0142(19891101)64:9<1901::AID-CNCR2820640924>3.0.CO
[3]  
2-W
[4]  
Courjal F, 1996, INT J CANCER, V69, P247
[5]   Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab [J].
Dybdal, N ;
Leiberman, G ;
Anderson, S ;
McCune, B ;
Bajamonde, A ;
Cohen, RL ;
Mass, RD ;
Sanders, C ;
Press, MF .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) :3-11
[6]  
FERLAY J, 2000, GLOBOCAN 2000 CANC I
[7]   Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J].
Harvey, JM ;
Clark, GM ;
Osborne, CK ;
Allred, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1474-1481
[8]   MAMMARY-CANCER - SELECTIVE ACTION OF THE ESTROGEN-RECEPTOR COMPLEX [J].
IP, M ;
MILHOLLAND, RJ ;
ROSEN, F ;
KIM, U .
SCIENCE, 1979, 203 (4378) :361-363
[9]  
KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355
[10]   Estrogen receptor expression in benign breast epithelium and breast cancer risk [J].
Khan, SA ;
Rogers, MAM ;
Khurana, KK ;
Meguid, MM ;
Numann, PJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (01) :37-42